Please login to the form below

Not currently logged in
Email:
Password:

Former Merck & Co exec to lead Seres

Roger Pomerantz was senior VP at pharma giant

Roger Pomerantz MerckSeres has appointed Dr Roger Pomerantz, formerly a senior figure at Merck & Co, to lead the company as CEO and chairman.

Dr Pomerantz was senior VP and worldwide head of licensing and acquisitions at Merck & Co, overseeing all licensing and acquisition activities at the company. This included external research and academic alliances.

He will now lead a company making advances in treat infectious diseases, with Seres' lead candidate a potential treatment for clostridium difficile (C. difficile).

Dr Pomerantz has considerable experience in the area of infectious diseases, serving as global franchise head of infectious diseases at Merck immediately prior to his role in licensing and acquisitions. 

Previously he was global head of infectious diseases for Johnson & Johnson having joined the company as president of its Tiobtec Pharmacueticals division, now known as Janssen Therapeutics.

In total Dr Pomerantz has been involved with the development of eight approved drugs for infectious diseases, covering HIV, hepatitis C and tuberculosis.

"With our lead product currently in clinical testing for the treatment of recurrent C. difficile, and a rapidly growing pipeline, Roger's expertise is ideally suited to provide the leadership that can execute on Seres' pioneering vision,” said Dr Noubar Afeyan, co-founder of Seres.

9th June 2014

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....